ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,636.00
-15.00 (-0.91%)
24 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -15.00 -0.91% 1,636.00 1,638.00 1,639.00 1,661.50 1,635.50 1,656.50 4,329,161 16:35:12
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.69 67.46B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,651p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £67.46 billion. Gsk has a price to earnings ratio (PE ratio) of 13.69.

Gsk Share Discussion Threads

Showing 32801 to 32819 of 33100 messages
Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older
DateSubjectAuthorDiscuss
03/1/2024
08:51
GSK is expected to guide for at least low single digit EPS growth for 2024 and settle the Zantac litigation case within the coming months, Jefferies analysts write in a research note as they raise their rating on the stock to buy from hold. They estimate that the pharma company will pay between $3bn and $4bn to settle the case. The company's growth profile is under appreciated and the current share price offers attractive risk reward.
dplewis1
03/1/2024
08:41
Wow that's some increase by Jefferies!!

I trade these and had a sell order in at 1498 before seeing the Times headline. Closed that and am hoping for a fair bit more now.

Good luck all 👍🏻

tuftymatt
03/1/2024
08:13
GSK : JEFFERIES RAISES TARGET PRICE TO 1,900P FROM 1,550PThis news story contains no content
mj19
03/1/2024
08:06
Nice to see this revving up for the start of the year
supermarky
03/1/2024
07:48
The Times have done a piece too about the GSK revival.

Does anyone have access to it?

Good luck all 👍🏻

tuftymatt
03/1/2024
03:55
Are Suitors circling GSK as Forbes had GSK in the top ten takeover targets??
halfpenny
03/1/2024
03:54
Latest on Takeover as mentioned in FORBES??
halfpenny
28/12/2023
08:25
"RSV: Jab for winter virus could cut baby hospitalisations by 80%, study says" - BBC
patientcapital
24/12/2023
15:47
Some snippets from the Sunday Times article: -

"GSK plans deal spree to boost drug pipeline

The pharmaceuticals giant GSK is set for a multibillion-pound buying spree of respiratory businesses as it seeks to reassure investors about its lacklustre pipeline, according to the man many see as heir to the chief executive’s throne."

...

"GSK will partially finance its buying spree with the cash generated by selling down its stake in Haleon, the consumer health firm behind Sensodyne toothpaste, that GSK spun off last year. In October, it raised about £900 million by selling down another chunk of its stake; it currently holds about 7 per cent of Haleon.

Miels ruled out deals in the “tens of billions” of dollars and said GSK was more focused on “very targeted single products or two products in a company”.

He added: “I think top priority is respiratory and auto-immune, [but]… we’re very busy across the board.”"

pj84
22/12/2023
09:41
On the Hansoh deal, GSK announced that it is in-licensing exclusive worldwide rights from China biopharmaceutical company, Hansoh Pharma, to develop and commercialize the latter’s investigational antibody-drug conjugate (ADC) candidate, HS-20093, in lung cancer and other solid tumor indications. However, Hansoh retains exclusive rights to the candidate in China’s mainland, Hong Kong, Macau, and Taiwan.

HS-20093 is a B7-H3 targeted ADC utilizing a clinically validated topoisomerase inhibitor payload. It is the second investigational ADC that GSK in-licensed from Hansoh.

It is important to note that in October 2023, GSK bought the first ADC from Hansoh, HS-20089. HS-20089 is a B7-H4 targeted ADC, currently being developed in China in mid-stage studies. Per GSK, HS-20089 has the potential to become a best-in-class treatment for ovarian and endometrial cancer with opportunities in other solid tumors.

Per the press release, HS-20093 is currently being evaluated in ongoing phase I and II studies in China. Data from the phase I ARTEMIS-001 study for HS-20093 in advanced solid tumors was recently presented at a medical conference. In the early-stage study, treatment with the candidate demonstrated initial clinical activity in small-cell lung cancer, non-small-cell lung cancer and sarcoma with multiple confirmed responses.

HS-20093 demonstrated a manageable safety profile, too, which was also encouraging.

tradermichael
21/12/2023
12:18
But the Hansoh Pharmaceutical Group deal is only $185 million upfront and the rest is if milestones are achieved. The Bellus deal, however, is an all-out acquisition and their product is well-advanced through trials and risk is minimal. Camlipixant is highly synergistic with GSK’s expertise and leadership in respiratory medicines and potentially adds a very important asset to GSK's portfolio for a chronic respiratory disease therapy. There are no approved medicines for refractory chronic cough (RCC) in the US and EU (for which there is a massive market).
tradermichael
21/12/2023
10:42
Another one for the balance sheet I expect.
alphorn
21/12/2023
08:02
GSK has entered into an exclusive license agreement with Hansoh Pharmaceutical Group for its HS-20093 antibody-drug cancer treatment, with payments of up to $1.71 billion depending upon milestones being met.

The companies said Wednesday that GSK will make an initial upfront payment of $185 million to Hansoh with the rest depending upon success-based milestones for HS-20093.

Upon commercialization of HS-20093, GSK will pay tiered royalties on global net sales outside of China's mainland, Hong Kong, Macau, and Taiwan, the companies said in a joint statement.

HS-20093 is being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple phase I and II clinical trials in China.

tradermichael
17/12/2023
13:46
Yes. If only we were lucky enough to have the world's biggest trading block on our doorstep and our square mile was the financial centre of said block. If only.
pcok
16/12/2023
09:04
Democrats, what do you expect?
tradermichael
15/12/2023
17:27
And now what? They have proof I take it???
mj19
15/12/2023
16:43
15 December 2023, 16:29Source - Alliance News


A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of ‘abusing’ the patent system to send prices higher, Bloomberg reported on Thursday.


The drugmakers have been accused of making sham patents to send prices higher and clip the wings of competition, the news agency reported, citing letters from Democrats Elizabeth Warren and Pramila Jayapal.


Astra’s Symbicort asthma treatment and GSK’s Advair and Flovent pair of inhalers are among the products mentioned in a letter sent by Warren to the drugmakers.





AstraZeneca shares were 2.6% lower at 10,193.58 pence each late Friday in London. GSK was down 2.8% at 1,420.40p. AbbVie was down 0.3% at $154.55 in New York.

beergut
15/12/2023
16:25
More likely to get £12 than a female hug
alibizzle
15/12/2023
16:12
IN @ £14.195895 (£20K for the 'Santa rally!') ..... ;o)
tradermichael
Chat Pages: 1324  1323  1322  1321  1320  1319  1318  1317  1316  1315  1314  1313  Older

Your Recent History

Delayed Upgrade Clock